Jason Harris


Osimertinib Still Holds The Crown in EGFR-Mutated Non-Small Cell Lung Cancer

November 19, 2022

As of November 2022, osimertinib is the preferred choice for the frontline treatment of EGFR-mutated non-small cell lung cancer. However, some experts believe that combination chemotherapy plus EGFR TKI will become a standard frontline treatment.